| Literature DB >> 31501615 |
E Crosetti1, A Bertolin2, G Molteni3, I Bertotto4, D Balmativola5, M Carraro1, A E Sprio6, G N Berta6, L Presutti7, G Rizzotto2, G Succo1,8.
Abstract
Entities:
Keywords: Laryngeal cancer; Multivariate analysis; Open partial horizontal laryngectomy; Recurrence; Supracricoid partial laryngectomy; Supratracheal partial laryngectomy
Mesh:
Substances:
Year: 2019 PMID: 31501615 PMCID: PMC6734199 DOI: 10.14639/0392-100X-2409
Source DB: PubMed Journal: Acta Otorhinolaryngol Ital ISSN: 0392-100X Impact factor: 2.124
Epidemiologic and clinical characteristics of patients treated by OPHL in the present series (N = 819).
| No of patients (%) | |||
|---|---|---|---|
| Age | Mean ± standard deviation | 60.2 ± 9.4 | |
| Range | 16-87 | ||
| Gender | Male | 755 (92.2%) | |
| Female | 64 (7.8%) | ||
| Arytenoid mobility | Normal | 581 (70.9%) | |
| Impaired/fixed | 238 (29.1%) | ||
| pT2 | N0 | 201 (31.8%) | 22 (11.8%) |
| N1 | 2 (0.3%) | 4 (2.2%) | |
| N2 | 3 (0.5%) | 4 (2.2%) | |
| pT3 | N0 | 291 (46.0%) | 86 (46.2%) |
| N1 | 13 (2.1%) | 11 (6.0%) | |
| N2 | 13 (2.1%) | 23 (12.4%) | |
| pT4 | N0 | 94 (14.7%) | 27 (14.4%) |
| N1 | 10 (1.6%) | 4 (2.2%) | |
| N2 | 6 (0.9%) | 5 (2.6%) | |
| Total | 633 (77.3%) | 186 (22.7%) | |
Stratification of patients (N = 819) according with the clinic-pathological parameters evaluated as possible risk factors for development of recurrences.
| Clinic-pathological parameters | Recurrences | Patients | |
|---|---|---|---|
| Negative | Positive | ||
| Positive | 119 (16.7%) | 21 (19.4%) | 140 (17.1%) |
| Negative | 592 (83.3%) | 87 (80.6%) | 679 (82.9%) |
| OPHL Type II | 620 (87.2%) | 77 (71.3%) | 697 (85.1%) |
| OPHL Type III | 91 (12.8%) | 31 (28.7%) | 122 (14.9%) |
| Supraglottic | 149 (21.0%) | 32 (29.6%) | 181 (22.1%) |
| Glottic | 556 (78.2%) | 73 (67.6%) | 629 (76.8%) |
| Other | 6 (0.8%) | 3 (2.8%) | 9 (1.1%) |
| pT1 | 3 (0.4%) | 2 (1.9%) | 5 (0.6%) |
| pT2 | 217 (30.5%) | 17 (15.7%) | 234 (28.6%) |
| pT3 | 385 (54.1%) | 51 (47.2%) | 436 (53.2%) |
| pT4 | 106 (14.9%) | 38 (35.2%) | 144 (17.6%) |
| pN0 | 645 (90.7%) | 76 (70.4%) | 721 (88.0%) |
| pN1 | 30 (4.2%) | 13 (12.0%) | 43 (5.3%) |
| pN2 | 36 (5.1%) | 19 (17.6%) | 55 (6.7%) |
| Basaloid | 10 (1.4%) | 3 (2.8%) | 13 (1.6%) |
| G1 | 179 (25.2%) | 11 (10.2%) | 190 (23.2%) |
| G2 | 326 (45.9%) | 45 (41.7%) | 371 (45.3%) |
| G3 | 196 (27.6%) | 49 (45.4%) | 245 (29.9%) |
| Positive | 116 (16.3%) | 50 (46.3%) | 166 (20.3%) |
| Negative | 595 (83.7%) | 58 (53.7%) | 653 (79.7%) |
| Positive | 194 (27.3%) | 43 (39.8%) | 237 (28.9%) |
| Negative | 517 (72.7%) | 65 (60.2%) | 582 (71.1%) |
| Positive | 119 (16.7%) | 39 (36.1%) | 158 (19.3%) |
| Negative | 592 (83.3%) | 69 (63.9%) | 661 (80.7%) |
| Positive | 19 (2.7%) | 10 (9.3%) | 29 (3.5%) |
| Negative | 692 (97.3%) | 98 (90.7%) | 790 (96.5%) |
| Positive | 18 (2.5%) | 11 (10.2%) | 29 (3.5%) |
| Negative | 693 (97.5%) | 97 (89.8%) | 790 (96.5%) |
| Positive | 55 (7.7%) | 13 (12.0%) | 68 (8.3%) |
| Close | 29 (4.1%) | 14 (13.0%) | 43 (5.3%) |
| Negative | 627 (88.2%) | 81 (75.0%) | 708 (86.4%) |
| Positive | 67 (9.4%) | 28 (25.9%) | 95 (11.6%) |
| Negative | 644 (90.6%) | 80 (74.1%) | 724 (88.4%) |
Treatments performed in the 819 patients.
| Type of treatment | N (%) |
|---|---|
| OPHL | |
| IIa | 159 (19.4%) |
| IIa + ARY | 354 (43.2%) |
| IIb | 46 (5.6%) |
| IIb + ARY | 138 (16.9%) |
| IIIa | 10 (1.2%) |
| IIIa + CAU | 99 (12.1%) |
| IIIb | 5 (0.6%) |
| IIIb + CAU | 8 (1.0%) |
ARY: arytenoid; CAU: crico-arytenoid unit.
Five-year Kaplan–Meier estimates of assessed oncologic outcomes.
| OS | DSS | DFS | FFL | LFS | LEDFS | |
|---|---|---|---|---|---|---|
| Patients with recurrent tumours | ||||||
| T | ||||||
| Endolaryngeal | 57.8% | 69.7% | 7.8% | 42.5% | 33.2% | 16.5% |
| Extralaryngeal | 64.8% | 88.9% | 0.0% | 38.1% | 27.8% | 0.0% |
| Indeterminate | 28.6% | 28.6% | 0.0% | 47.6% | 28.6% | 14.3% |
| N | ||||||
| Level II-V | 42.5% | 63.9% | 5.3% | 74.8% | 37.1% | 25.1% |
| Level VI | 51.2% | 63.3% | 11.1% | 59.5% | 41.4% | 20.8% |
| M | ||||||
| Positive | 40.0% | 43.6% | 9.5% | 81.3% | 33.9% | 21.8% |
| Patients with non-recurrent tumours | 93.4% | 98.9% | 100% | 99.8% | 93.2% | 93.1% |
OS: overall survival; DSS: disease-specific survival; DFS: disease-free survival; FFL: freedom from laryngectomy; LFS: laryngectomy-free survival; LEDFS, laryngo-oesophageal dysfunction-free survival.
Analyses of factors predicting recurrence.
| Variable | Univariate analysis | Logistic regression model | ||
|---|---|---|---|---|
| Score test | P value | Score test | P value | |
| Previous treatments | 0.604 | 0.437 | 0.038 | 0.846 |
| Type of surgery | 14.118 | < 0.001 | 4.928 | 0.026 |
| Tumour site | 1.131 | 0.288 | 0.932 | 0.334 |
| pT subcategory | 16.389 | < 0.001 | 0.100 | 0.752 |
| pN ≥ 1 staging | 15.742 | < 0.001 | 15.643 | < 0.001 |
| Grading | 6.481 | 0.011 | 1.299 | 0.254 |
| Cartilage involvement | 38.174 | < 0.001 | 24.221 | < 0.001 |
| Vascular invasion | 3.725 | 0.054 | 0.857 | 0.355 |
| Perineural invasion | 15.062 | < 0.001 | 6.018 | 0.014 |
| Delphian node pN+ | 5.033 | 0.025 | 0.155 | 0.694 |
| Extranodal extension | 16.620 | < 0.001 | 2.253 | 0.133 |
| Status of margins | 6.124 | 0.013 | 1.253 | 0.263 |
| Adjuvant treatments | 14.393 | < 0.001 | 0.859 | 0.354 |